Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
The addition of lithium to perphenazine altered the pattern of plasma homovanillic acid (HVA) during the course of treatment for acute psychosis. In the perphenazine-treated group plasma HVA declined significantly by days 7-9 of treatment, whereas in the perphenazine-plus-lithium group plasma HVA tended to increase. The pattern for plasma methoxyhydroxyphenethyl-glycol (MHPG) was not significantly different for the two groups. The addition of lithium to a neuroleptic may enhance the metabolism of dopamine.
Bowers
M B
MB
Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Mazure
C M
CM
Nelson
J C
JC
Jatlow
P I
PI
D000328:Adult; D000368:Aged; D001714:Bipolar Disorder / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D008094:Lithium / Q000008:administration & dosage*; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood*; D008875:Middle Aged; D010546:Perphenazine / Q000008:administration & dosage*; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D008734:Methoxyhydroxyphenylglycol; D008094:Lithium; D010546:Perphenazine; D006719:Homovanillic Acid